Abbott Laboratories (ABT) Stock: A SWOT Analysis
The price-to-earnings ratio for Abbott Laboratories (NYSE: ABT) is above average at 33.39x, Company’s 36-month beta value is 0.75.Analysts have differing opinions on the stock,
The price-to-earnings ratio for Abbott Laboratories (NYSE: ABT) is above average at 33.39x, Company’s 36-month beta value is 0.75.Analysts have differing opinions on the stock,
Abbott Laboratories (NYSE: ABT)’s stock price has plunge by -0.20relation to previous closing price of 109.11. Nevertheless, the company has seen a -1.47% plunge in
The stock of Abbott Laboratories (ABT) has seen a -2.16% decrease in the past week, with a -6.82% drop in the past month, and a
The stock price of Abbott Laboratories (NYSE: ABT) has plunged by -1.38 when compared to previous closing price of 113.66, but the company has seen
Abbott Laboratories (NYSE: ABT) has a price-to-earnings ratio that is above its average at 33.69x. The stock has a 36-month beta value of 0.73. Opinions
Despite the failure of baby food, Abbott Laboratories (NYSE: ABT) was able to improve revenues in the first quarter because of diversification. Abbott Laboratories was
Manufacturer DexCom Inc. (DXCM) has long been the sole provider of a continuous glucose level monitoring system. This generated strong sales and rapid stock growth
© 2024, Fueled by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.